Acromegaly and pituitary gigantism

E4_ACROMEG

hyperpituitarism: Disease of the glandular, anterior portion of the pituitary (pituitary gland, anterior) resulting in hypersecretion of adenohypophyseal hormones such as growth hormone; prolactin; thyrotropin; luteinizing hormone; follicle stimulating hormone ; and adrenocorticotropic hormone. Hyperpituitarism usually is caused by a functional adenoma.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 E22.0

Hospital discharge: ICD-9 2530

Hospital discharge: ICD-8 2530

Hospital discharge: excluded ICD-8 25301

Cause of death: ICD-10 E22.0

Cause of death: ICD-9 2530

Cause of death: ICD-8 2530

Cause of death: excluded ICD-8 25301

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

Check minimum number of events None

Include endpoints None

154

E4_ACROMEG

Extra metadata

Level in the ICD hierarchy 4

First used in FinnGen datafreeze DF2

Parent code in ICD-10 E22

Name in latin Acromegalia

Similar endpoints

↥

List of similar endpoints to Acromegaly and pituitary gigantism based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

All

Female

Male

Number of individuals

150

Unadjusted prevalence (%)

0.05

0.04

Mean age at first event (years)

44.66

43.86

45.91

?

Follow-up

Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.

Absolute risk

Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).

Number of individuals (N)

Number of individuals having the current endpoint and died during the follow-up time.
Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: E4_ACROMEG – Acromegaly and pituitary gigantism
GWS hits: 0

Survival analyses between endpoints

↥

Plot

before Acromegaly and pituitary gigantism
after Acromegaly and pituitary gigantism

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Acromegaly and pituitary gigantism

↥